Similar articles

• Clinical trials of PGE1, PGI2 and mimetics in patients with peripheral vascular disease.

  Sinzinger H, Virgolini I, O'Grady J. Sinzinger H, et al. Prog Clin Biol Res. 1989;301:85-96. Prog Clin Biol Res. 1989. PMID: 2477859 Review. No abstract available.
• Potential therapeutic mechanisms of stable prostacyclin (PGI2)-mimetics in severe peripheral vascular disease.

  Müller B, Krais T, Stürzebecher S, Witt W, Schillinger E, Baldus B. Müller B, et al. Biomed Biochim Acta. 1988;47(10-11):S40-4. Biomed Biochim Acta. 1988. PMID: 2470358 Clinical Trial.
• Iloprost in peripheral vascular disease--platelet function and clinical outcome.

  Fitscha P, Tiso B, Sinzinger H. Fitscha P, et al. Prog Clin Biol Res. 1987;242:463-8. Prog Clin Biol Res. 1987. PMID: 2444993 Clinical Trial. No abstract available.
• Pharmacological treatment for Buerger's disease.

  Cacione DG, Macedo CR, do Carmo Novaes F, Baptista-Silva JC. Cacione DG, et al. Cochrane Database Syst Rev. 2020 May 4;5(5):CD011033. doi: 10.1002/14651858.CD011033.pub4. Cochrane Database Syst Rev. 2020. PMID: 32364620 Free PMC article.
• [Treatment of the peripheral vascular diseases with prostaglandin].

  Miyauchi Y. Miyauchi Y. Nihon Rinsho. 1994 Aug;52(8):2182-6. Nihon Rinsho. 1994. PMID: 7933609 Review. Japanese.